Study summary

The same IL-17 antibody doubled remission in polymyalgia rheumatica

Secukinumab in polymyalgia rheumatica · 381 people, phase 3 · Published June 2026, New England Journal of Medicine

41.2%in sustained remission at 52 weeks, vs 20.4% with placebo

What was tested

Secukinumab against placebo, each with a 24-week steroid taper, for relapsing polymyalgia rheumatica, a condition that often occurs with GCA.

What they found

Sustained remission was 41.2% (300 mg) and 40.6% (150 mg) vs 20.4% with placebo.
Total steroid dose was about 25% lower.

What it means

A new option for the related condition, polymyalgia rheumatica; GCA and PMR now appear to respond differently to IL-17 blockade.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.